Evidence map›Paper›PMID 40526143›Full record

ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025

Comparison of histological response across patients with Ewing sarcoma treated with preoperative chemotherapy with or without preoperative radiotherapy.

Hisaki Aiba, Ayano Aso, Alberto Righi, Marco Gambarotti, Silvia Cammelli, Paolo Spinnato, Matteo Traversari, Ahmed Atherley, Konstantina Solou, Hiroaki Kimura and 6 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hisaki AibaClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. hisakiaiba@yahoo.co.jp.
Ayano AsoClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Alberto RighiDepartment of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Marco GambarottiDepartment of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Silvia CammelliRadiation Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Paolo SpinnatoDiagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Matteo TraversariClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Ahmed AtherleyClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Konstantina SolouClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Hiroaki KimuraDepartment of Orthopedic Surgery, Nagoya City University, Nagoya, Japan.
Hideki MurakamiDepartment of Orthopedic Surgery, Nagoya City University, Nagoya, Japan.
Federica ZuccheriClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Barbara DozzaDepartment of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum University of Bologna, Bologna, Italy.
Giorgio FregaOsteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Davide DonatiClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Costantino ErraniClinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to compare the histological response, a surrogate preoperative treatment efficacy marker, of patients treated with preoperative chemotherapy with or without preoperative radiotherapy. Moreover, local recurrence in both groups was investigated.

methodsSurgical specimens from 210 patients with Ewing sarcoma were assessed between 2003 and 2020 to evaluate their histological response to preoperative treatment; 181 patients received preoperative chemotherapy, while 29 received both preoperative chemotherapy and radiotherapy. The histological response rate in the surgical section was assessed based on tumour necrosis and reparative fibrous tissue.

resultsThe median histological response rates were 100% (interquartile range = 83-100%) for the preoperative chemotherapy and radiotherapy group and 90% (interquartile range = 60-100%) for the preoperative chemotherapy group (P = 0.004). Multivariate logistic regression analysis indicated that the administration of the preoperative radiotherapy (Odds ratio = 3.36 [95% confidence interval, CI 1.32-8.54]; P = 0.011) and small tumour volume (< 200 mL) were associated with the achievement of > 95% histological response (Odds ratio = 0.52 [95% CI 0.27-0.99]; P = 0.047). Local recurrence occurred in 9.9% (18/181) of patients who received preoperative chemotherapy and in 2.4% (1/29) of patients who received both preoperative chemotherapy and radiotherapy (P = 0.258).

conclusionPreoperative radiotherapy might enhance histological response, potentially reducing local recurrence. Therefore, it should be considered for patients with Ewing sarcoma who are at high risk of local recurrence or may have inadequate surgical margins.

Indexed as

Bone NeoplasmsNeoadjuvant TherapySarcoma, EwingAdolescentAdultChemotherapy, AdjuvantChildChild, PreschoolFemaleHumansMaleNeoplasm Recurrence, LocalPreoperative CareRetrospective StudiesTreatment OutcomeYoung AdultChemotherapyEwing sarcomaHistological responsePreoperative radiotherapyRecurrence

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.